Effect of rabeprazole versus famotidine on platelet inhibition in patients with normal clopidogrel responsiveness
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2013
Price : $35 *
At a glance
- Drugs Rabeprazole (Primary) ; Famotidine
- Indications Cardiovascular disorders; Gastrointestinal disorders
- Focus Pharmacodynamics
- Acronyms ACCEL-PROTECT
- 17 Oct 2013 New trial record
- 03 Sep 2013 Primary endpoint 'Platelet-aggregation' has not been met.
- 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.